Introduction Retrograde ureteroscopy with holmium laser lithotripsy (HLL) is a standard treatment for urolithiasis. Moses technology has been shown to improve fragmentation efficiency in vitro; however, it is still unclear how it performs clinically compared to standard HLL. We performed a systematic review and meta-analysis evaluating the differences in efficiency and outcomes between Moses mode and standard HLL. Material and methods We searched the MEDLINE, EMBASE, and CENTRAL databases for randomized clinical trials and cohort studies comparing Moses mode and standard HLL in adults with urolithiasis. Outcomes of interest included operative (operation, fragmentation, and lasing times; total energy used; and ablation speed) and perioperative parameters (stone-free rate and overall complication rate). Results The search identified six studies eligible for analysis. Compared to standard HLL, Moses was associated with significantly shorter average lasing time (mean difference [MD]-0.95, 95% confidence in-terval [CI]-1.22 to-0.69 minutes), faster stone ablation speed (MD 30.45, 95% CI 11.56–49.33 mm3/min), and higher energy used (MD 1.04, 95% CI 0.33–1.76 kJ). Moses and standard HLL were not significantly different in terms of operation (MD-9.89, 95% CI-25.14 to 5.37 minutes) and fragmentation times (MD-1.71, 95% CI-11.81 to 8.38 minutes), as well as stone-free (odds ratio [OR] 1.04, 95% CI 0.73–1.49) and overall complication rates (OR 0.68, 95% CI 0.39–1.17). Conclusions While perioperative outcomes were equivalent between Moses and standard HLL, Moses was associated with faster lasing time and stone ablation speeds at the expense of higher energy usage.
All Science Journal Classification (ASJC) codes